Scales to Assess Impulsive and Compulsive Behaviors in Parkinson’s Disease: Critique and Recommendations

Andrew H. Evans, FRACP, MD,1* David Okai, MRCPsych, MB, BS,2 Daniel Weintraub, MD,3,4 Shen-Yang Lim, FRACP, MD,5 Sean S. O’Sullivan, FRCP, PhD,5,6 Valerie Voon, MD, PhD,7 Paul Krack, MD, PhD,8 Cristina Sampaoio, MD,9 Bart Post, MD, PhD,10 Albert F.G. Leentjens, PhD,11 Pablo Martinez-Martín, MD, PhD,12 Glenn T. Stebbins, PhD,13 Christopher G. Goetz, MD,13 Anette Schrag, MD, PhD,14 and the Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee

1Department of Neurology, the Royal Melbourne Hospital, Parkville, Australia
2Kings College London, Institute of Psychiatry, Section of Cognitive Neuropsychiatry, London, UK
3Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
4Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (Philadelphia Parkinson’s Disease Research, Education and Clinical Center (PADRECC) and Mental Illness Research Education Clinical, Centers of Excellence (MiRECC)), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
5Division of Neurology, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia
6Department of Neurology, Bon Secours Hospital, Cork, Ireland
7Department of Psychiatry, University of Cambridge, Cambridge, UK
8Movement Disorders Center, Department of Neurology, University Hospital (Inselspital) and University of Bern, Bern Switzerland
9Cure Huntington’s Disease InitiativeEl (CHDI) Management/CHDI Foundation, Princeton, New Jersey, USA
10Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
11Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands
12National Center of Epidemiology and Centro de Investigacion Biomedica en Red sobre Enfermedades Neurolégegenativas (CIBERNED), Carlos III Institute of Health, Madrid, Spain
13Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
14Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK

ABSTRACT: Impulse control disorders (ICDs) and related impulsive and compulsive behaviors (together called ICBs) have been increasingly recognized in the context of Parkinson’s disease (PD) and treatment. The International Parkinson’s and Movement Disorder Society commissioned a task force to assess available clinical screening instruments and rating scales, including their clinimetric properties, make recommendations regarding their utility, and suggest future directions in scale development and validation. The literature was systematically searched for scales measuring a range of reported ICBs in PD. A scale was designated “recommended” if the scale had been employed in PD studies, been used beyond the group that developed it, and had adequate clinimetric data published for PD. Numerous diagnostic screening tools and severity rating scales were identified for a range of ICBs, including compulsive medication use, punding/hobbyism, walkabout, pathological gambling, hypersexuality, compulsive or binge eating, compulsive buying, reckless driving, compulsive exercise, pyromania, trichotillomania, hoarding, kleptomania, intermittent explosive disorder, and internet addiction. For screening across the range of ICBs (except compulsive medication use), the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP) and QUIP-Rating Scale (QUIP-RS) are recommended, and for severity rating across the range of ICBs the QUIP-RS and the Ardouin Scale of Behavior in Parkinson’s Disease are recommended. The Scale for Outcomes in Parkinson’s Disease–Psychiatric Complications is recommended for rating of hypersexuality and the compulsive behaviors gambling/shopping. Further testing of established scales against gold standard diagnostic criteria is urgently required for all other individual ICBs in PD. © 2019 International Parkinson and Movement Disorder Society

Key Words: impulse control disorders; Parkinson’s disease; clinimetrics; rating scales; validity; reliability

*Correspondence to: Dr. Andrew H. Evans, Department of Neurology, The Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia; E-mail: Andrew.Evans@mh.org.au

Relevant conflicts of interests/financial disclosures: Nothing to report.

Published online 00 Month 2019 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27689
Impulsive and compulsive behaviors (ICBs) have been increasingly recognized in the context of Parkinson’s disease (PD) treatment. These ICBs are linked by their repetitive, reward, or incentive-based natures and include a range of impulse control disorders (ICDs) (ie, pathological gambling [PG], hypersexuality [HS], compulsive or binge eating [CE], compulsive buying [CB]) as well as related behaviors, including punding, walkabout, and compulsive medication use (CMU), the latter also known as dopamine dysregulation syndrome (DDS).

ICDs are defined by a failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or to others. The largest systematic prevalence study in North American PD outpatients estimated that at least 14% have 1 or more current ICDs according to criteria.

Cross-sectional evaluations of PD outpatient populations indicate that ICDs are more prevalent when compared with the general population or with control participants and are associated with the drugs used to treat the motor symptoms of PD. However, the prevalence estimates of ICDs in PD vary widely from 3.5% to 35%, reflecting variability in case ascertainment, definitions, prescribing practices, and cultural factors. Recently, the 5-year cumulative incidence of ICDs in treated PD was estimated at 46.1%.

ICDs in PD increase caregiver burden and adversely affect occupational functioning, finances, and interpersonal relationships. Despite this, ICBs frequently go unrecognized and represent a major clinical challenge for routine detection, potentially prolonging the psychosocial consequences associated with them. ICBs also represent a major management challenge once identified.

Simple, short, self-administered but sensitive screening questionnaires are therefore needed to potentially prevent or detect ICBs in clinical practice. Rating scales are required to aid categorization and measurement of the symptom severity, support entry criteria for research studies, assist in neurobiological studies, and measure and test clinical responses to psychosocial and medication treatments as part of clinical trials. Uniform diagnostic criteria for ICDs in PD currently do not exist but would aid generalizability of the study of vulnerability factors and outcomes to clinical practice.

For these reasons, the International Parkinson and Movement Disorder Society (MDS) commissioned a systematic review of the clinimetric properties of the screening tools and scales used to detect, diagnose, and rate ICBs in PD. MDS-sponsored reviews of scales for assessing other aspects of PD have already been published, and the methodology of this review is similar.

Methods

Administrative Organization and Critique Process

The steering committee of the MDS task force on rating scales for PD invited the chair (AHE) to form a task force to critique existing ICD rating scales. This group used the same working methods as previous task forces. The review used a proforma that includes descriptive properties, availability, content, use, acceptability, clinimetric properties, and overall impression in patients with PD.

Two task force members reviewed each scale. The completed reviews were then assessed by all other members following the terminology used in the development of the appendix of ancillary scales to complement the MDS-sponsored revision of the UPDRS.

The official definitions for critiques are the following: “recommended” for diagnostic screening or severity rating of ICBs if for this purpose (1) it has been applied to PD populations, (2) there are data on its use in studies beyond 1 group, and (3) it has been studied clinimetrically and adequate clinimetric data are reported in PD (for this review that the instrument was found to be adequate for screening purposes, measuring severity of symptoms, or assessing responsiveness to change); “suggested” if it has been applied to PD populations but only 1 of the other criteria applies; or “listed” if it has only been applied to PD populations. The scales classified as suggested or recommended and have at least some validation data in PD are listed in the tables, with only the recommended scales included in the results. The full results of all scales, including those that are used in PD but only validated in non-PD populations, are available in the appendix. The ratings of recommended, suggested, and listed have been applied to the following 2 different uses: screening tools to detect the presence or absence of ICBs and severity rating scales to detect the magnitude of ICD impact.

Literature Search Strategy

We searched for scales that were designed to screen/diagnose and measure the severity of ICBs and were either used in studies with PD patients up to February 2018. We searched Medline and PubMed databases: search terms used included (Parkinson’s disease OR Parkinsonism) AND (impulse control disorder OR compulsive OR gambling OR hypersexuality OR paraphilia OR eating OR addiction OR hoarding OR dopamine dysregulation syndrome OR hedonistic homeostatic dysregulation OR punding OR obsessive-compulsive OR reckless OR buying OR shopping). Published or in press peer-reviewed papers and their references or abstracts known to the task force members were also considered in this review.

Results

A total of 50 scales used for whole or individual ICBs were identified. We describe those instruments that met the criteria for “recommended” and give further details on all reviewed instruments in the appendix, including their description, clinimetric data, and scope of use.
Table 1 lists all instruments fulfilling criteria for the recommended or suggested scales to measure the presence or absence of ICBs.

**Instruments for the Range of ICBs**

**The Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP)**

The QUIP was developed as a screening instrument for ICDs and related behaviors. The authors of the QUIP reviewed existing scales for ICDs, solicited input from outside experts in the area of ICDs in PD, and structured the ICD questions to be consistent with diagnostic criteria or defining clinical characteristics as described in the Diagnostic and Statistical Manual Edition IV-Text Revised. The full version was divided into the following 3 sections: (1) 5 questions (including an introductory question describing the problem behaviors) for the 4 most common ICDs reported in PD, (2) 3 distinct introductory questions and 2 additional questions for hobbyism, punding, and walkabout; and (3) 5 questions (including an introductory question) for CMU. A shortened version of the ICD section was constructed (QUIP-S) using 2 questions for each disorder (8 total questions).

**Use in PD and Extent of Use.** The QUIP was developed and validated in PD and has been used by the developers and many other groups.

**Clinimetric Properties.** The individual QUIP subscales were validated against a gold standard, semistructured interview for PG, CB, HS, CE, DDS, punding, hobbyism, and walkabout. The discriminant validity of the QUIP was high for each disorder or behavior (receiver operating characteristic area under the curve [AUC]: pathological gambling = 0.95, hyper sexuality = 0.97, compulsive buying = 0.87, compulsive eating = 0.88, punding = 0.78, hobbyism = 0.93, walkabout = 0.79). On post hoc analysis, the QUIP-S ICD section had similar properties (receiver operating characteristic AUC: gambling = 0.95, sexual behavior = 0.96, buying = 0.87, eating = 0.88). When disorders/behaviors were combined, the sensitivity of the QUIP to detect an individual with any disorder was 96%. The sensitivity of the QUIP for a diagnosed ICD was 100% for both patient-completed and informant-completed instruments, and specificity was 75% for both raters. Agreement between patient-reporting and informant-reporting of any ICD behaviors on the QUIP was moderate (averaged \( \kappa = 0.41 \)), and for individual ICDs was highest for gambling (\( \kappa = 0.55 \)) and lowest for eating (\( \kappa = 0.40 \)). However, approximately 40% of patients without an ICD diagnosis were found to have a positive QUIP, suggesting either overidentification or that many PD patients experience subsyndromal ICD symptoms that require ongoing monitoring.

**Strengths and Weaknesses.** The QUIP is currently the only validated screening instrument for the most commonly reported ICDs in PD. It is self-rated and brief with generally good diagnostic accuracy overall for most individual ICDs. However, it does not enquire about a change in preference for sweet foods that may miss some aspects of compulsive eating behavior. It has limited sensitivity for punding and walkabout (60%-65%) and limited validity for CMU. It is not designed to evaluate the severity of ICBs. There is poor agreement between the informant’s and patient’s ratings of ICBs in subsequent studies.

**Final Assessment.** The QUIP fulfills criteria for a recommended scale for measuring for a range of ICBs, except punding, walkabout, and CMU, as it fulfills all 3 criteria, but has not been evaluated as a measure of severity (Table 1).

**The Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease—Rating Scale (QUIP-RS)**

The QUIP-RS is a brief 28-item patient-reported or clinician-rated scale that was developed in PD and derived from the QUIP for measure of severity of ICDs. Each item is rated on a 5-point Likert scale assessing frequency of symptoms with a range of scores from 0 (never) to 4 (very often). The questions relate to the 4 most common ICDs (PG, CE, CB, and HS), hobbyism, and punding (combined as a single diagnosis), and CMU during the preceding 4 weeks.

**Use in PD and Extent of Use.** At a movement disorders clinic, a convenience sample of PD patients self-completed the QUIP-RS and were administered a semistructured diagnostic interview by a blinded trained rater to assess the discriminant validity for impulse control disorders (n = 104) and related disorders (n = 77). The QUIP-RS has been used by others.

**Clinimetric Properties.** To determine criterion validity of the self-completed QUIP-RS (n = 104), participants were administered a semistructured diagnostic interview for PG, CB, HS, and CE, and a subset of participants was also administered a diagnostic interview for hobbyism, punding, and DDS. A diagnosis of compulsive gambling included those patients with either problem or pathological gambling. The optimal cutoff point for individual ICDs (possible score 0-16 for each ICD) were as follows: pathological gambling ≥8 (positive and negative likelihood ratios (LR+ and LR−) LR+ = 33.33, LR− = 0.00, AUC = 0.997), compulsive buying ≥8 (LR+ = 16.40, LR− = 0.19, AUC = 0.969), hyper sexuality ≥8.
(LR+ = 9.09, LR− = 0.00, AUC = 0.979), and compulsive and binge eating ≥7 (LR+ = 4.35, LR− = 0.16, AUC = 0.913). For combined ICDs (possible score 0-64), the optimal cutoff point was ≥10 (LR+ = 5.38, LR− = 0.17, AUC = 0.907). Hobbyism-punding (possible score 0-32) had an optimal cutoff point of ≥7 (LR+ = 5.29, LR− = 0.12, AUC = 0.873). However, others have reported sensitivities and specificities that were not as good. Cut-off points for CMU screening have not been established and therefore not validated. The reliability between patient-rating and clinician-rating and test–retest reliability (intraclass correlation coefficient) were >0.60 for all disorders. Interrater reliability between different raters when clinician rated has not been assessed. The QUIP-RS was validated against a number of other neuropsychiatric measures. It has been used as an outcome measure and shows sensitivity to change. Participants in an ICD treatment randomized controlled trial showed significant (P = .04) improvement on active (naltrexone) when compared with placebo treatment on the QUIP-RS, with estimated changes in QUIP-RS ICD scores from baseline to week 8 of 14.9 points (naltrexone) versus 7.5 points (placebo).

**Strengths and Weaknesses.** The QUIP-RS appears to be valid and reliable for the rating of severity of ICDs in PD, but not DDS. Preliminary results suggest that it can also be used to support as a screening tool for ICDs as well as to monitor changes in symptom severity over time. The cut-off points established in the North American sample may not be generalizable. The QUIP-RS is yet to be widely used.

**Final Assessment.** The QUIP-RS is recommended as a diagnostic screening tool for ICDs, except DDS, because it has been applied to a PD population, fulfills necessary clinimetric criteria, and has been used beyond the group that developed the scale. Likewise, it is Recommended as a severity rating tool for measuring the magnitude of ICD impact (Table 1).

**Ardouin Scale of Behavior in Parkinson’s Disease (ASBP)**

The Ardouin Scale is a semi-structured interview that assesses neuropsychiatric modifications routinely encountered in PD. The scale is rated by a psychiatrist or a psychologist familiar with PD so the validity for use with other trained raters is uncertain. The timeframe assessed is the month preceding the interview. Items are rated on a five-point scale from 0 (absence of disorder or change compared with usual behavior) to 4 (severe behavioral disorder) accounting for the severity and the

---

**TABLE 1. Conclusions Regarding Scale Classification for Impulsive and Compulsive Behaviors (ICBs)**

<table>
<thead>
<tr>
<th>Scale</th>
<th>Used in PD</th>
<th>Use by other investigators in PD</th>
<th>Adequate clinimetrics in non-PD and further clinimetrics in PD</th>
<th>Classification for diagnostic screening</th>
<th>Classification for severity rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scales covering the range of ICBs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>Recommended</td>
<td>N/A</td>
</tr>
<tr>
<td>QUIP-Rating Scale (QUIP-RS)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>Recommended</td>
<td>Recommended</td>
</tr>
<tr>
<td>Self-Assessment Scale For Dopamine Dependent Behaviors in Parkinson’s Disease (Ardouin short screen)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>N/A</td>
<td>Recommended</td>
</tr>
<tr>
<td>Scale for Outcomes in Parkinson’s Disease–Psychiatric Complications (SCOPA-PC)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>N/A</td>
<td>Recommended for hypersexuality, gambling/shopping</td>
</tr>
<tr>
<td>Minnesota Impulsive Disorders Interview (MIDI)</td>
<td>x</td>
<td>x</td>
<td></td>
<td>Suggested</td>
<td>N/A</td>
</tr>
<tr>
<td>The Parkinson’s Impulse Control Scale (PICS)</td>
<td>x</td>
<td></td>
<td></td>
<td>Suggested</td>
<td>N/A</td>
</tr>
<tr>
<td>Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s Disease (SEND-PD)</td>
<td>x</td>
<td></td>
<td></td>
<td>Suggested</td>
<td>N/A</td>
</tr>
<tr>
<td>Parkinson’s Disease Dopamine Dysregulation Syndrome-Patient and Caregiver Inventory (DDS-PC)</td>
<td>x</td>
<td></td>
<td></td>
<td>Suggested</td>
<td>N/A</td>
</tr>
<tr>
<td>Scales focusing on individual ICBs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Oaks Gambling Screen (SOGS)</td>
<td>x</td>
<td>x</td>
<td></td>
<td>Suggested</td>
<td>Suggested</td>
</tr>
<tr>
<td>Evans’ Punding Screen and Rating Scale</td>
<td>x</td>
<td>x</td>
<td></td>
<td>Suggested</td>
<td>Listed</td>
</tr>
<tr>
<td>Punding Rating Scale</td>
<td>x</td>
<td></td>
<td></td>
<td>Suggested</td>
<td>Suggested</td>
</tr>
<tr>
<td>Shorter version of the Sexual Addiction Screening Test (PD-SAST)</td>
<td>x</td>
<td></td>
<td></td>
<td>Suggested</td>
<td>Suggested</td>
</tr>
<tr>
<td>Saving Inventory–Revised(SI-R)</td>
<td>x</td>
<td></td>
<td></td>
<td>Suggested</td>
<td>Suggested</td>
</tr>
<tr>
<td>The Pathological Gambling Adaption of the Yale-BrownObsessive-Compulsive Scale (PG-YBOCS)</td>
<td>x</td>
<td></td>
<td></td>
<td>N/A</td>
<td>Suggested</td>
</tr>
<tr>
<td>Gambling Symptom Assessment Scale (G-SAS)</td>
<td>x</td>
<td></td>
<td></td>
<td>N/A</td>
<td>Suggested</td>
</tr>
<tr>
<td>Compulsive Buying Scale (CBS)</td>
<td>x</td>
<td></td>
<td></td>
<td>N/A</td>
<td>Suggested</td>
</tr>
</tbody>
</table>

N/A, not applicable.
frequency of the disorder compared with premorbid usual functioning and its psychosocial effect. Individual items are grouped in three subscales. The “hypodopaminergic” behavior subscale includes changes in behavior that can be attributed to the loss of dopaminergic neurons—i.e., depressed mood, anxiety, irritability and aggressiveness, hyperemotionality, and apathy. The subscale evaluating non-motor neuropsychiatric fluctuations includes non-motor ON and OFF individual items that assess ON state euphoria and OFF state dysphoria in fluctuating patients. The hyperdopaminergic behaviors subscale measures the presence and the severity of behavioral disorders typically induced by dopaminergic treatment. These include hypomanic mood, psychotic signs, nocturnal hyperactivity, diurnal somnolence, increased eating behavior, creativity, hobbyism, punding, risk-taking behavior, compulsive shopping, pathological gambling, hypersexuality, “dopaminergic addiction,” and overall excess in motivation (i.e., the opposite of apathy). The Aresdon scale—items, questions, rating guidelines, and advice on how to conduct the interview—has been published within its validation study.37

Use in PD and Extent of Use. The scale has been used by the authors36-37 and has been validated in PD in a multicenter, international study38 and has been used in a RCT multicenter trial.39

Clinimetric Properties. Designed specifically for PD, 260 patients were assessed with the tool for ICDs. For test–retest reliability, the weighted kappa coefficient for items was higher than 0.40 except for risk-taking behavior and dopaminergic addiction. The interrater reliability showed kappa values higher than 0.50 for most of the items except for nocturnal hyperactivity, risk-taking behavior, and dopaminergic addiction. The interrater reliability showed kappa values higher than 0.50 for most of the items except for nocturnal hyperactivity, risk-taking behavior, and dopaminergic addiction. Cronbach’s alpha coefficient for domains ranged from 0.69 to 0.78. Correlations with corresponding rating scales for depression, anxiety, and apathy were appropriate for all domains (p = 0.56-0.82).

Strengths and Weaknesses. Comprehensive (approximately 2 hours) standardized tool with acceptable internal consistency, convergent validity, and test-retest and inter-rater reliability for its individual components for most subscores except risk-taking behavior, dopaminergic addiction and nocturnal hyperactivity. Designed for use in PD but not validated beyond use of psychiatrist/psychologist raters. Has been used in a large multicenter binational RCT of DBS. Criterion validity not reported. Some reservations about face validity for some of the subscales (e.g., identifying aggression as a hypodopaminergic behavior). Some terms are not in widespread use (e.g., hyperemotionality).

Final Assessment. The scale for dopamine-dependent behaviors was used as a rating tool prior to validation studies. However, this scale fulfills the criteria for recommended as a severity scale on the basis that it has been studied for this purpose in PD studies and has adequate clinimetric properties.

The Scale for Outcomes in Parkinson’s Disease—Psychiatric Complications (SCOPA-PC)

The SCOPA-PC is a screening and severity scale that consists of a 7-item clinician-rated, semi-structured questionnaire administered to the patient and caregiver for the preceding month. It assesses a broad range of psychiatric symptoms, including 2 items that relate to compulsive behaviors (1 item for hypersexuality and 1 combined item for compulsive shopping and pathological gambling). The scores range from 0 (no symptoms) to 3 (severe symptoms).

Use in PD and Extent of Use. The scale has been used by the authors40,41 and other groups.42-44

Clinimetric Properties. The SCOPA-PC was designed specifically for PD and validated in 106 PD patients for validation. Interrater and test–retest reliability indexes (weighted kappa) of the sexual preoccupation (0.87 and 0.88, respectively) and compulsive behavior (0.96 and 0.73, respectively) items were high. Among 106 patients, 15% had sexual preoccupation item >0 and 10% had compulsive behavior item >0. The compulsive behavior had good correlation with the ICD item of the Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s Disease (rs = 0.52).42

Strengths and Weaknesses. This is a brief and standardized tool with adequate reliability and validity demonstrated for the 2 items. It is designed for use in PD.

The SCOPA-PC has been evaluated for ICB severity only, not as a screening tool. It covers only hypersexuality and compulsive behavior, combining gambling and shopping, and does not allow distinction between them. No studies have examined change with treatment. In application of the scale, it is recommended by the authors that information is used from both patient and caregiver, but no data are provided about the level of agreement between patient and caregiver questions.

Final Assessment. The SCOPA-PC has not been used as a diagnostic screening tool. However, this scale fulfills the criteria for recommended as a severity scale for hypersexuality and the compulsive behaviors of gambling/shopping on the basis that it has been validated for this purpose in PD studies, used by more than 1 research group, and has adequate clinimetric properties.
Discussion

The systematic review of the available literature yielded a large number of studies and instruments that have attempted to ascertain the prevalence and severity of ICBs in various PD cohorts.

PD itself may not confer an increased risk for development of impulse control or related behavior symptoms. Given that approximately 20% of newly diagnosed PD patients report some symptoms, long-term follow-up is needed to determine if such patients are at increased risk for ICD development. Categorical rating tools that are quick and easy to administer can help clinicians screen for ICBs, identify ICBs early in their course, aid decisions regarding treatment that may include prevention, and monitor pharmacological and nonpharmacological management. Moreover, it is desirable to screen for multiple ICBs in patients displaying 1 abnormal behavior, as the presence of multiple ICBs in a given individual are associated with more severe depression, poorer quality of life, and treatment resistance. The adequate validation of a scale to screen for multiple ICBs in a PD population has been demonstrated for the QUIP and the QUIP-RS. The QUIP is a categorical assessment tool that screens for a range of ICBs, but although it is sensitive to patients with an ICD it has some limitations. For instance, nearly 40% of patients without an ICD diagnosis screen positive on the QUIP—the authors suggested that this is because many PD patients experience sub-syndromal ICD symptoms.

However, a critical point is the current definition of an ICD is as “failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or to others” (as described in the DSM-IV-TR).

The QUIP and QUIP-RS include questions specific to the urge of performing a particular behavior, mediated by ventral striatal systems. This does not necessarily involve the execution of that behavior (ie, with increased involvement of dorsal striatal systems). This discrepancy may contribute to the high percentage of positive at QUIP not confirmed by semistructured interview. This contrasts with the definition of CMU in the QUIP, which requires the act of medication taking leading to harmful effects.

Conversely, dimensional rating tools can assist clinical research to help practitioners understand the etiology and course of ICBs and identify the effects of treatments to improve clinical outcomes and potentially monitor patients in remission. The QUIP-RS currently has the best validity for rating a range of ICBs in PD, and cutoffs were established for individual ICBs; however, the generalizability of cutoff points to non–North American samples is lacking. Furthermore, the Ardouin short screen has also been demonstrated adequate clinimetrics for rating severity of a range of ICBs. The SCOPA-PC was designed, and is recommended, to provide a dimensional assessment of hypersexuality and the compulsive behaviors gambling/shopping, but cannot be used as a diagnostic tool.

This work identified the need for the validity of rating scales developed in non-PD to be demonstrated for the most common behaviors in PD, particularly PG, CE, and CB, before deciding to develop new scales specific to PD. Moreover, rarely have such scales been compared directly to non-PD populations or been applied to nonwhite populations where dopamine agonists, for instance, are less commonly prescribed. An ongoing issue is that the agreement between patient and informant reporting of symptoms is not high, with no clear direction for the mismatches in reporting. Patient underreporting of ICBs is likely more common, indicating a likely complex relationship between insight and addiction.

Despite the urgent need to understand ICBs further, not all scales developed for non-PD populations will be suitable for adaptation to PD, and it may not be possible to transfer the results from other studies. There are important overlaps in the risk factors for ICBs in PD and non-PD populations, but there are also important differences. These differences may impact on the application of scales developed in non-PD populations to PD patients with regard to the interpretation of the results and drawing conclusions about ICB in PD. For instance, the phenomenology of CE in PD is likely to be distinct from eating disorders affecting adolescents. Moreover, a scale developed to detect sexually risky behavior in HIV-positive individuals (ie, the Sexual Compulsivity Scale) may not be useful in PD patients, in whom hypersexual behavior is more likely to impair longstanding personal and social relationships, add financial burden, and rarely leads to forensic issues. Finally, relatively little focus has been given in existing scales to the social and occupational impact of ICBs, with a preference for the proxy measure of frequency/intensity and a focus on caregiver or social burden.

A further difficulty that this review encountered was that most ICD scale validations have been performed against the Diagnostic and Statistical Manual Edition IV–Text Revised, but this is not an uncontroversial gold standard for ICDs and compulsive medication use. PG, binge-eating disorder, and hoarding are included in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, but there are no formal Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for compulsive buying, hypersexuality, and puning. Furthermore, there are many more behaviors described than can be routinely assessed in an assessment tool. In this regard, a clinical interview is still
likely to be the best mechanism to identify harmful behaviors. These issues are further complicated by the uncertainty in the psychiatric literature about the classification of ICDs as to whether ICDs represent “behavioral addictions,” and therefore share the neurobiological underpinnings of substance dependence disorders or should be classified as an obsessive-compulsive spectrum disorder. In conclusion, this review has highlighted the need for further research on screening and rating scales for ICBs in PD. Although validity testing for screening/diagnostic purposes has been done for most ICB scales, validity testing of severity scales (eg, correlation with scales assessing similar construct) has been done very rarely. At the present time, we do not recommend the development of a new scale until the available scales are more fully assessed.

Members of the MDS Rating Scales Review Committee

Roongroj Bhidayasiri, MD, FRCP, FRCPs; Richard G. Brown, PhD; Johan Marinus, PhD; Tiago A. Mestre, MD, MSc; Mayela Rodriguez Violante, MD, MSc, Matej Skorvanek, MD, PhD.

References


